Search This Blog

Friday, July 30, 2021

CDC: Delta seems more dangerous than other COVID-19 variants, contagious as chicken pox

 An internal Centers for Disease Control and Prevention document obtained by several news outlets warns that the COVID-19 delta variant could be more likely to produce severe illness and can spread as fast as chickenpox.


The Washington Post, which was first to report on the CDC slide presentation, said new research also indicates that fully vaccinated people can spread the virus at higher rates than previously thought. The paper reported that the CDC document says health officials need to acknowledge the "war has changed."

The CDC did not immediately respond to an after-hours email from Fox News. The information in the document reportedly played a role in the new mask guidelines announced earlier this week. The Biden administration has been more assertive in recent days to compel Americans to sign up for a vaccine due to the emergence of variants.


Admiral Brett Giroir, the former assistant health secretary under President Trump, told Fox News’ "America Reports" on Thursday that the variant is so contagious that it is "just a matter of time" before everyone who is not vaccinated and hasn’t had COVID-19 comes down with the infection.

"If you have prior immunity you do have some protection, but more and more data are telling us that that protection is not so good against delta," he said. "Remember, you can get the flu every year. It’s not because your immunity isn’t good. It’s because the flu changes and delta is really a new strain that is different than everything we’ve seen. So, I am really concerned that natural immunity, although real, is not going to be sufficient against Delta."

Giroir’s comments seem to echo the CDC’s document. The agency said there needs to be a new public messaging to get people to sign up for the vaccine.

There have been lingering issues for those resistant to the vaccines. The Food and Drug Administration has not fully approved the jabs that are still being administered under an Emergency Use Authorization. 

The death count in the U.S. also remains comparatively low. There were 398 deaths due to the virus on Thursday in the U.S. compared to the winter months when the numbers were 10 times that amount. 

Matthew Seeger, a communication expert at Wayne State University, told the Post that health officials may have had some messaging issues with the public.

"We’ve done a great job of telling the public these are miracle vaccines," he said. "We have probably fallen a little into the trap of over-reassurance, which is one of the challenges of any crisis communication circumstance."

The Post’s report pointed out that fully vaccinated people who come down with the delta variant can carry the same viral load as those without the vaccine and infect others.

The New York Times, which also viewed the document, reported that Dr. Rochelle P. Walensky, the head of the CDC, has said transmission from vaccinated individuals is rare, but some scientists believe it is more common than earlier believed.

John Moore, a virologist at Weill Cornell Medicine, told the Times that Delta "is the troubling variant we already knew it was."


"But the sky isn’t falling and vaccination still protects strongly against the worse outcomes," he said.

https://www.foxnews.com/health/delta-covid-chickenpox

Biden wants state, local govts to pay $100 to newly vaccinated Americans

 President Joe Biden is calling for state, local and U.S. territorial governments to provide $100 payments for every newly vaccinated American to boost COVID-19 inoculation rates, the U.S. Treasury Department said on Thursday.

The Treasury said in a statement that such incentives are an allowable use of funds from the $350 billion in aid granted to state, local, territorial and tribal governments under the American Rescue Plan Act. The department added that it would provide technical assistance in using these funds to support increased vaccinations.

The Treasury also said it was expanding a tax credit that employers could claim for wages paid to employees to give them paid time off to get vaccinated or to assist family members and certain other individuals with COVID-19 vaccinations.

"Today, the President is calling on state, territorial, and local governments to provide $100 payments for every newly vaccinated American, as an extra incentive to boost vaccination rates, protect communities, and save lives," Treasury said in a statement.

Earlier on Thursday, New York City Mayor Bill de Blasio announced that anyone getting their first COVID-19 vaccine shot at a city-run site would receive a $100 payment.

https://news.yahoo.com/biden-wants-state-local-govts-193528335.html

Mixing Russia's Sputnik V, AstraZeneca shots proves safe in small trial

 Trials mixing a first dose of the Russian-made Sputnik V vaccine with AstraZeneca’s shot revealed no serious side effects and no subsequent cases of coronavirus among volunteers, the Russian Direct Investment Fund (RDIF) said on Friday.

The trial involved 50 people and began in Azerbaijan in February, RDIF, which is responsible for marketing Sputnik V vaccine abroad, said in the statement.

Full results of the trial, including data on the immune response produced by the combination vaccine, would be published next month, RDIF said.

Both the Sputnik V and the AstraZeneca shot are viral vector vaccines that are based on a first dose followed by a booster.

Such viral vector shots use harmless modified viruses as vehicles, or vectors, to carry genetic information that helps the body build immunity against future infections.

The first dose of Sputnik V is based on adenovirus type 26, while AstraZeneca’s COVID-19 vaccine, developed together with Oxford University, uses a chimpanzee adenovirus vector.

Russia on Monday gave the green light for clinical trials combining the British shot and Sputnik V to go ahead across five Russian clinics.

https://www.reuters.com/article/us-health-coronavirus-russia-astrazeneca/mixing-russias-sputnik-v-astrazeneca-shots-proves-safe-in-small-trial-rdif-idUSKBN2F00ZC

Japan Expands State of Emergency as COVID-19 Surge Shadows Olympics

 Japan decided on Friday to expand states of emergency to three prefectures near Olympic host Tokyo and the western prefecture of Osaka, as COVID-19 cases spike in the capital and around the country, overshadowing the Summer Games.

Tokyo, already under its fourth state of emergency since the pandemic began, on Friday announced 3,300 new cases, after a record 3,865 the day before. The surge is beginning to strain the medical system, with 64% of Tokyo's hospital beds available for serious COVID-19 cases already filled as of mid-week.

The new emergency measures will be in effect from Aug. 2-Aug. 31, while existing states of emergency for Tokyo and southern Okinawa island will be extended to Aug. 31, said Prime Minister Yoshihide Suga, who announced the latest measures.

Japan has avoided a devastating COVID-19 outbreak, but is now struggling to contain the highly transmissible Delta variant, with daily cases nationwide topping 10,000 for the first time on Thursday, with 10,687 new cases.

Economy Minister Yasutoshi, who is spearheading Japan's COVID-19 response, said the rise in cases had not peaked.

"The situation is extremely severe," he told parliament.

Japan has imposed a series of "state of emergency" declarations, but the orders are mostly voluntary, unlike other countries which impose strict lockdowns.

Many people have grown weary of stay-home requests, with some bars refusing to adhere to service restrictions, and Japan's vaccination rollout lags.

Health Minister Norihisa Tamura said the country had entered a new "extremely frightening" stage as cases are spiking even though the movement of people was not increasing, and that the Delta variant was a big factor.

"I think that people cannot see ahead and, worrying how long this situation will last, they find it unbearable that they cannot return to normal daily life," he told the panel.

The surge in COVID-19 cases is bad news for Suga, whose support rates are already at their lowest since he took office last September and who faces a ruling party leadership race and general election later this year.

Suga and Olympics organisers have denied there is any link between the July 23-Aug. 8 Summer Games and the recent sharp spike in cases.

Unlike the voluntary restrictions and low vaccination rates elsewhere in Japan, the Olympic village in Tokyo for athletes and coaches boasts more than 80% vaccination, testing is compulsory and movement is stringently curtailed.

Athletes and other attendees from around the world must follow strict rules to prevent any spread of the virus within the "Olympic bubble" or to the wider city. Spectators are banned from most venues.

Organisers on Friday reported 27 new Games-related COVID-19 cases including three athletes, bringing the total since July 1 to 220.

But experts worry holding the Games has sent a confusing message to the public about the need to limit activities.

Less than 30% of residents of Japan are fully vaccinated. Nishimura repeated that all those who want to get vaccinated should be able to do so by October or November.

https://www.usnews.com/news/world/articles/2021-07-29/japan-proposes-adding-four-regions-to-covid-19-emergency-minister

Siemens Healthineers 3Q Profit, Revenue Rose

 Siemens Healthineers AG said Friday that it raised its full-year outlook after increased third-quarter net profit and revenue, as sales of its rapid Covid-19 antigen tests reached their peak during the pandemic.

The German medical-equipment maker posted a net profit of 390 million euros ($463.1 million), compared with EUR270 million in the same period of the prior year.

Revenue increased to EUR5.00 billion from EUR3.31 billion, the company said.

The result was supported by the doubling of revenue from the company's diagnostics segment, including a EUR600 million contribution from rapid Covid-19 tests, and considerable growth in the imaging and advanced therapies units, the company said.

The Erlangen-based company raised its guidance for the year for comparable revenue growth to between 17% and 19%, from 14% to 17% previously. It also revised its adjusted basic earnings-per-share range to between EUR1.95 and EUR2.05, from EUR1.90 to EUR2.05.

The changed outlook is based on the higher revenue expectations for the imaging segment, as well as for rapid Covid-19 antigen tests of the diagnostics segment compared with the previous outlook from the second quarter of 2021, the company said.

"With significant growth in revenue, earnings and cash flow, the strong business momentum from the previous quarters continued," Chief Executive Bernd Montag said.

https://www.marketscreener.com/quote/stock/SIEMENS-HEALTHINEERS-AG-42379342/news/Siemens-Healthineers-3Q-Profit-Revenue-Rose-36013538/

Takeda Pharmaceutical's First-Quarter Net Profit More Than Doubled

 Takeda Pharmaceutical Co. said Friday that its first-quarter net profit more than doubled compared with the same period a year earlier thanks partly to sales of diabetes-related products.

The Japanese drug maker said that net profit for the quarter ended June 30 rose to 200.38 billion yen ($1.83 billion) from Y82.51 billion a year earlier. That beat the estimate of Y138.42 billion from a poll of analysts by S&P Global Market Intelligence.

First-quarter revenue increased 18% from a year earlier to Y949.60 billion.

Takeda sold diabetes products in Japan to Teijin Pharma Ltd. for Y133.0 billion in April, helping its quarterly earnings.

Takeda's operating profit margin improved to 26.2% from 20.9% a year earlier.

Takeda maintained its revenue and net-profit forecasts for its fiscal year ending March. It expects revenue to increase 5.4% to Y3.370 trillion and net profit to fall 34% to Y250.00 billion.

https://www.marketscreener.com/quote/stock/TAKEDA-PHARMACEUTICAL-COM-6491073/news/Takeda-Pharmaceutical-s-First-Quarter-Net-Profit-More-Than-Doubled-36014134/

Merck sees recovery in non-COVID vaccine demand as quarterly sales beat estimates

 

Merck & Co reported quarterly revenue on Thursday that topped Wall Street estimates, as sales of its Gardasil vaccine bounced back and demand for blockbuster cancer drug Keytruda remained strong.

Sales of non-COVID-19 vaccines and physician-administered drugs are expected to recover as hospitals and clinics have started to adapt to the impact of the pandemic, Merck executives told investors.

Merck, which failed in its efforts to produce a coronavirus vaccine, expects to have late-stage data for its COVID-19 antiviral, molnupiravir, in October, Chief Financial Officer Caroline Litchfield said.

The U.S. drugmaker in June agreed to provide 1.7 million doses of the treatment being developed with Ridgeback Biotherapeutics to the United States government for around $1.2 billion once it is cleared by regulators. Merck is also in supply talks with other countries.

Demand for Gardasil, its vaccine to prevent cancers linked to the human papillomavirus, recovered sharply in the second quarter as patients started to catch up on routine medical visits skipped at the height of the pandemic.

Gardasil sales jumped 88% to $1.23 billion, beating analysts' estimates of $991.38 million.

Recent improvements in the supply chain for the vaccine will drive "very strong sequential and year-over-year growth for Gardasil in the back half of the year, especially in ex-U.S. markets," said Franklin Clyburn, president of Merck's human health business.

Sales of cancer immunotherapy Keytruda rose 23% to $4.18 billion in the quarter, in line with estimates.

The company's top growth driver is on track to become the world's best-selling drug by 2023.

Merck on Thursday said it had the financial flexibility to consider deals of all sizes and would focus on assets that could add to its strength in the cancer market.

"We want to build upon that strength and actually see ourselves as a company that over time can be a broad player across oncology," said Merck's new Chief Executive Officer Robert Davis on an investor call.

"One of the areas we continue to believe we do not need to go is to the very large synergy-driven deals. I think we have enough firepower in our own pipeline," he added.

The company's second-quarter sales rose 22% to $11.40 billion, beating estimates of $11.10 billion.

Merck reported adjusted earnings of $1.31 per share for the quarter, in-line with analyst estimates. Its share were down 1% in early trading.

https://www.marketscreener.com/news/latest/Merck-sees-recovery-in-non-COVID-vaccine-demand-as-quarterly-sales-beat-estimates--36000666/